Free Republic

Anthony Fauci, the government's top infectious diseases expert, on Friday called new trial results for a Merck pill to treat COVID-19 "impressive," as experts say the treatment could be a key tool in the pandemic fight. "The data are impressive," Fauci said at a White House press briefing, noting he was briefed by the company on its results on Thursday night. Merck said in a press release that the trial found that its drug cut the risk of hospitalization or death by 50 percent. Eight trial participants who received a placebo died, compared to zero who received the drug from...

At the start of the pandemic, researchers began testing existing antivirals in people hospitalized with severe Covid-19. But many of those trials failed to show any benefit from the antivirals. In hindsight, the choice to work in hospitals was a mistake. Scientists now know that the best time to try to block the coronavirus is in the first few days of the disease, when the virus is replicating rapidly and the immune system has not yet mounted a defense. In a trial of hospitalized patients, however, molnupiravir seemed to have no effect on the disease. In April, the companies announced...

Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, could be the first oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide." The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with...

KEY POINTS A phase 3 trial of Merck and Ridgeback Biotherapeutics’ oral antiviral treatment molnupiravir showed it reduced the risk of hospitalization or death by around 50% in Covid patients. Merck plans to seek emergency use authorization in the U.S. and submit marketing applications to other global drug regulators. If authorized by regulatory bodies, molnupiravir could be the first oral antiviral medicine for Covid. “The company, when they briefed us last night, had mentioned that they will be submitting their data to the FDA imminently,” White House chief medical advisor Dr. Anthony Fauci said at a Covid briefing Friday.

@MaajidNawaz The patent for ivermectin had expired, so Pfizer needed to redesign it in order to sell it under a new patent. Pfizer is laughing at us all, and MSM went along like suckers. The public was deceived for profit once again. As per Dr @PierreKory “there are 44 published, peer-reviewed studies of IVM in COVID - 11 Double blind RCT's, 12 open RCT's, 1 single blind RCT, 2 PSM OCT's- nearly all showing MASSIVE benefits..+ >30 non-RCT's show the same. NIH could give a weak/cautious rec.. but wont. Insane” “Ivermectin fights 21 viruses, incl. SARS-CoV-2, the cause of Covid-19....